# US 2026/0216081 A1 · Metformin hydrochloride enteric-coated preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216081 A1
- Document ID: US20260216081A1
- Status: Published application
- Kind: A1
- Application number: 19/147,455
- Filed: 2024-07-20
- Published: 2026-07-30
- Earliest claimed: 2023-08-22
- Assignees: Yayan (Tianjin) Biomedical Technology Center (Limited Partnership)
- Applicants: Yayan (Tianjin) Biomedical Technology Center (Limited Partnership)
- Inventors: Qian GAO; Wei WANG; Tao DONG
- Web page: https://patentgrep.com/patent/US20260216081A1

## CPC

- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An enteric-coated preparation of metformin hydrochloride, which is an oral dosage form made of a therapeutically effective amount of a biguanide compound and a pharmaceutically acceptable excipient. The said enteric-coated preparation of metformin hydrochloride has a dissolution rate of no more than 15% in a pH 4.5 medium within 120 minutes, and a dissolution rate of no less than 85% in a pH 6.8 medium within 20 minutes, preferably a dissolution rate of no more than 7.5% in a pH 4.5 medium within 120 minutes, and a dissolution rate of no less than 85% in a pH 6.8 medium within 15 minutes. The enteric-coated preparation of metformin hydrochloride with the drug dissolution technology improves the gastrointestinal tolerance of metformin hydrochloride without reducing or even improving the hypoglycemic efficacy, reduces adverse reactions caused by the drug, and can be taken before, after or during meals.

## Claims

### Claim 1

An enteric-coated preparation of a biguanide compound, which is an oral dosage form made of a therapeutically effective amount of a biguanide compound and a pharmaceutically acceptable excipient, characterized in that: the dissolution rate of the biguanide compound in the enteric-coated preparation in a pH 4.5 medium within 120 minutes is not higher than 15%, and the dissolution rate of the biguanide compound in a pH 6.8 medium within 20 minutes is not lower than 85%.

### Claim 2 (depends on 1)

The enteric-coated preparation according to claim 1, characterized in that the dissolution rate of the biguanide compound in the enteric-coated preparation in a pH 4.5 medium within 120 minutes is not higher than 7.5%, and the dissolution rate of the biguanide compound in a pH 6.8 medium within 15 minutes is not lower than 85%.

### Claim 3 (depends on 1)

The enteric-coated preparation according to claim 1, characterized in that, compared with an immediate-release preparation containing an equal amount of the biguanide compound, the said enteric-coated preparation has a relative bioavailability of 60% to 80%.

### Claim 4 (depends on 1)

The enteric-coated preparation according to claim 1, wherein the biguanide compound is metformin or a pharmaceutically acceptable salt thereof; preferably, the biguanide compound is metformin hydrochloride.

### Claim 5 (depends on 1)

The enteric-coated preparation according to claim 1, the oral dosage form is a tablet, capsule or granule.

### Claim 6 (depends on 1)

Use of a biguanide compound or a salt thereof for preparing a medicament for reducing adverse events caused by a biguanide compound, wherein the medicament is an enteric-coated preparation according to claim 1.

### Claim 7 (depends on 1)

Use of a biguanide compound or a salt thereof in the preparation of a medicament for treating metabolic disorders, wherein the medicament is an enteric-coated preparation according to claim 1.

### Claim 8 (depends on 1)

Use of a biguanide compound or a salt thereof in the preparation of a medicament for diabetes, wherein the medicament is an enteric-coated preparation according to claim 1.

### Claim 9 (depends on 1)

Use of a biguanide compound or a salt thereof in the preparation of a medicament for reducing body weight, wherein the medicament is an enteric-coated preparation according to claim 1.

### Claim 10 (depends on 1)

Use of a biguanide compound or a salt thereof for preparing a drug that can be taken before, after or during meals to improve patients' compliance with medication, wherein the drug is an enteric-coated preparation according to claim 1.
